Reuters logo
BRIEF-Halozyme provides update on Abbvie collaboration
2016年11月21日 / 下午1点47分 / 10 个月前

BRIEF-Halozyme provides update on Abbvie collaboration

Nov 21 (Reuters) - Halozyme Therapeutics Inc :

* Halozyme Therapeutics Inc - abbvie has discontinued a development program using halozyme enhanze platform technology

* Halozyme - co, abbvie will continue to work to identify additional targets for co-development under 2015 global collaboration,licensing agreement

* Halozyme Therapeutics - abbvie has discontinued development program following completion of a phase 1 study in which target results were not achieved

* Halozyme Therapeutics-abbvie discontinued development program using halozyme enhanze platform technology, tnf-alpha target after completion of phase 1 study

* Halozyme provides update on abbvie collaboration Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below